Net Income (Loss) Attributable to Parent in USD of Oncotelic Therapeutics, Inc. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Oncotelic Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q3 2025.
  • Oncotelic Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$1,047,365.000, a 68.3% increase year-over-year.
  • Oncotelic Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$1,669,158.000, a 64.2% increase year-over-year.
  • Oncotelic Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$4,523,932.000, a 42.8% increase from 2023.
  • Oncotelic Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$7,903,093.000, a 255% decline from 2022.
  • Oncotelic Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $5,094,981.000.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Oncotelic Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$1,669,158 -$1,047,365 +$2,257,121 +68.3% 01 Jul 2025 30 Sep 2025 10-Q 17 Nov 2025
Q2 2025 -$3,926,279 $277,856 +$487,693 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025
Q1 2025 -$4,413,972 -$298,716 +$109,960 +26.9% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 -$4,523,932 -$600,933 +$135,050 +18.4% 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2025
Q3 2024 -$4,658,982 -$3,304,486 -$3,419,795 -29.7% 01 Jul 2024 30 Sep 2024 10-Q 17 Nov 2025
Q2 2024 -$1,239,187 -$209,837 +$6,547,163 +96.9% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025
Q1 2024 -$7,786,350 -$408,676 +$116,743 +22.2% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 -$7,903,093 -$735,983 +$4,553,439 +86.1% 01 Oct 2023 31 Dec 2023 10-K 15 Apr 2025
Q3 2023 -$12,456,532 $115,309 +$893,244 01 Jul 2023 30 Sep 2023 10-Q 19 Nov 2024
Q2 2023 -$13,349,776 -$6,757,000 -$22,769,119 -1.4% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 $9,419,343 -$525,419 +$4,324,362 +89.2% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q4 2022 $5,094,981 -$5,289,422 -$3,495,268 -1.9% 01 Oct 2022 31 Dec 2022 10-K 12 Apr 2024
Q3 2022 $8,590,249 -$777,935 +$784,593 +50.2% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 $7,805,656 $16,012,119 +$19,243,399 01 Apr 2022 30 Jun 2022 10-Q 18 Aug 2023
Q1 2022 -$11,437,743 -$4,849,781 -$2,046,701 -73% 01 Jan 2022 31 Mar 2022 10-Q 22 May 2023
Q4 2021 -$9,391,042 -$1,794,154 +$1,646,088 +47.8% 01 Oct 2021 31 Dec 2021 10-K/A 20 Apr 2023
Q3 2021 -$11,037,130 -$1,562,528 +$424,029 +21.3% 01 Jul 2021 30 Sep 2021 10-Q 18 Nov 2022
Q2 2021 -$11,461,159 -$3,231,280 -$3,813,371 -6.6% 01 Apr 2021 30 Jun 2021 10-Q 22 Aug 2022
Q1 2021 -$7,647,788 -$2,803,080 +$1,854,814 +39.8% 01 Jan 2021 31 Mar 2021 10-Q 23 May 2022
Q4 2020 -$9,502,602 -$3,440,242 +$41,472 +1.2% 01 Oct 2020 31 Dec 2020 10-K 15 Apr 2022
Q3 2020 -$9,544,074 -$1,986,557 -$995,431 -1% 01 Jul 2020 30 Sep 2020 10-Q 22 Nov 2021
Q2 2020 -$8,548,643 $582,091 +$1,771,201 01 Apr 2020 30 Jun 2020 10-Q 20 Aug 2021
Q1 2020 -$10,319,844 -$4,657,894 -$3,681,831 -3.8% 01 Jan 2020 31 Mar 2020 10-Q 24 May 2021
Q4 2019 -$6,638,013 -$3,481,714 -$3,327,111 -21.5% 01 Oct 2019 31 Dec 2019 10-K 15 Apr 2021
Q3 2019 -$3,310,902 -$991,126 -$777,093 -3.6% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020
Q2 2019 -$2,533,809 -$1,189,110 -$1,035,802 -6.8% 01 Apr 2019 30 Jun 2019 10-Q 16 Nov 2020
Q1 2019 -$1,498,007 -$976,063 -$785,269 -4.1% 01 Jan 2019 31 Mar 2019 10-Q 16 Nov 2020
Q4 2018 -$712,738 -$154,603 +$2,279,397 +93.6% 01 Oct 2018 31 Dec 2018 10-K 14 May 2020
Q3 2018 -$2,992,135 -$214,033 +$3,321,967 +93.9% 01 Jul 2018 30 Sep 2018 10-Q 19 Nov 2019
Q2 2018 -$6,314,102 -$153,308 +$3,730,692 +96.1% 01 Apr 2018 30 Jun 2018 10-Q 19 Nov 2019
Q1 2018 -$10,044,794 -$190,794 +$3,767,206 +95.2% 01 Jan 2018 31 Mar 2018 10-Q 19 Nov 2019
Q4 2017 -$13,812,000 -$2,434,000 +$1,018,000 +29.5% 01 Oct 2017 31 Dec 2017 10-K 10 Apr 2019
Q3 2017 -$14,830,000 -$3,536,000 -$300,000 -9.3% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018
Q2 2017 -$14,530,000 -$3,884,000 -$243,000 -6.7% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018
Q1 2017 -$14,287,000 -$3,958,000 -$633,000 -19% 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018
Q4 2016 -$13,654,000 -$3,452,000 +$514,000 +13% 01 Oct 2016 31 Dec 2016 10-K 17 Apr 2018
Q3 2016 -$14,168,000 -$3,236,000 +$356,000 +9.9% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017
Q2 2016 -$14,524,000 -$3,641,000 -$317,000 -9.5% 01 Apr 2016 30 Jun 2016 10-Q 02 Aug 2017
Q1 2016 -$14,207,000 -$3,325,000 -$553,000 -19.9% 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017
Q4 2015 -$13,654,000 -$3,966,000 -$1,328,000 -50.3% 01 Oct 2015 31 Dec 2015 10-K 30 Mar 2017
Q3 2015 -$12,326,000 -$3,592,000 -$142,000 -4.1% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016
Q2 2015 -$12,184,000 -$3,324,000 +$605,000 +15.4% 01 Apr 2015 30 Jun 2015 10-Q 02 Aug 2016
Q1 2015 -$12,789,000 -$2,772,000 -$142,000 -5.4% 01 Jan 2015 31 Mar 2015 10-Q 06 May 2016
Q4 2014 -$12,647,000 -$2,638,000 -$541,000 -25.8% 01 Oct 2014 31 Dec 2014 10-K 25 Mar 2016
Q3 2014 -$12,106,000 -$3,450,000 -$804,000 -30.4% 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015
Q2 2014 -$11,302,000 -$3,929,000 -$2,275,000 -1.4% 01 Apr 2014 30 Jun 2014 10-Q 06 Aug 2015
Q1 2014 -$9,027,000 -$2,630,000 -$750,000 -39.9% 01 Jan 2014 31 Mar 2014 10-Q 07 May 2015
Q4 2013 -$8,277,000 -$2,097,000 -$422,000 -25.2% 01 Oct 2013 31 Dec 2013 10-K 30 Mar 2015
Q3 2013 -$7,855,000 -$2,646,000 -$399,000 -17.8% 01 Jul 2013 30 Sep 2013 10-Q 13 Nov 2014
Q2 2013 -$7,456,000 -$1,654,000 +$612,000 +27% 01 Apr 2013 30 Jun 2013 10-Q 08 Aug 2014
Q1 2013 -$8,068,000 -$1,880,000 +$11,000 +0.58% 01 Jan 2013 31 Mar 2013 10-Q 08 May 2014
Q4 2012 -$8,079,000 -$1,675,000 +$670,000 +28.6% 01 Oct 2012 31 Dec 2012 10-K 30 Mar 2015
Q3 2012 -$8,749,000 -$2,247,000 +$1,266,000 +36% 01 Jul 2012 30 Sep 2012 10-Q 13 Nov 2013
Q2 2012 -$10,015,000 -$2,266,000 +$666,000 +22.7% 01 Apr 2012 30 Jun 2012 10-Q/A 18 Oct 2013
Q1 2012 -$10,681,000 -$1,891,000 -$1,028,000 -1.2% 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013
Q4 2011 -$9,653,000 -$2,345,000 01 Oct 2011 31 Dec 2011 10-K 20 Mar 2014
Q3 2011 -$3,513,000 +$10,023,000 +74% 01 Jul 2011 30 Sep 2011 10-Q 09 Nov 2012
Q2 2011 -$2,932,000 -$5,469,000 -2.2% 01 Apr 2011 30 Jun 2011 10-Q 13 Aug 2012
Q1 2011 -$863,000 01 Jan 2011 31 Mar 2011 10-Q 11 May 2012
Q3 2010 -$13,536,000 01 Jul 2010 30 Sep 2010 10-Q 10 Nov 2011
Q2 2010 $2,537,000 01 Apr 2010 30 Jun 2010 10-Q 12 Aug 2011

Oncotelic Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$4,523,932 +$3,379,161 +42.8% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025
2023 -$7,903,093 -$12,998,074 -2.6% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025
2022 $5,094,981 +$14,486,023 01 Jan 2022 31 Dec 2022 10-K 12 Apr 2024
2021 -$9,391,042 +$111,560 +1.2% 01 Jan 2021 31 Dec 2021 10-K/A 20 Apr 2023
2020 -$9,502,602 -$2,864,589 -43.2% 01 Jan 2020 31 Dec 2020 10-K 15 Apr 2022
2019 -$6,638,013 -$5,925,275 -8.3% 01 Jan 2019 31 Dec 2019 10-K 15 Apr 2021
2018 -$712,738 +$13,099,262 +94.8% 01 Jan 2018 31 Dec 2018 10-K 14 May 2020
2017 -$13,812,000 -$158,000 -1.2% 01 Jan 2017 31 Dec 2017 10-K 10 Apr 2019
2016 -$13,654,000 $0 0% 01 Jan 2016 31 Dec 2016 10-K 17 Apr 2018
2015 -$13,654,000 -$1,007,000 -8% 01 Jan 2015 31 Dec 2015 10-K 30 Mar 2017
2014 -$12,647,000 -$4,370,000 -52.8% 01 Jan 2014 31 Dec 2014 10-K 25 Mar 2016
2013 -$8,277,000 -$198,000 -2.5% 01 Jan 2013 31 Dec 2013 10-K 30 Mar 2015
2012 -$8,079,000 +$1,574,000 +16.3% 01 Jan 2012 31 Dec 2012 10-K 30 Mar 2015
2011 -$9,653,000 +$14,117,000 +59.4% 01 Jan 2011 31 Dec 2011 10-K 20 Mar 2014
2010 -$23,770,000 01 Jan 2010 31 Dec 2010 10-K 15 Mar 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.